Arich Enterprise Co., Ltd. AI Stock Analysis
Arich Enterprise Co., Ltd. (4173) AI Stock Analysis
Arich Enterprise Co., Ltd.
(TPEx:4173)
The score is held back primarily by weak and highly volatile cash generation — a NT$1.91bn operating cash outflow this year — combined with margin compression that caused profits to fall despite double-digit revenue growth and low returns on capital (ROE ~4.3%). Partially offsetting this are a stable ~20% gross margin, a consistent growth trajectory, a manageable debt-to-equity ratio of 0.32, and an attractive 5.83% dividend yield. Technicals are mildly supportive with the price above its short- and medium-term averages and a positive MACD, but it still trades below the 200-day average and is near the top of its recent range. At 22.4x earnings, the valuation leaves limited room for disappointment until cash conversion and margins improve.
Arich Enterprise Co., Ltd. (4173) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 1.34B
- Dividend Yield
- 5.81%
- Average Volume (3M)
- 60.86K
- Price to Earnings (P/E)
- 22.4
- Beta (1Y)
- 0.16
- Revenue Growth
- 10.77%
- EPS Growth
- -35.84%
- Country
- TW
- Employees
- 198
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Distribution
Arich Enterprise Co., Ltd. Business Overview & Revenue Model
Company Description
Established in 1969 and headquartered in New Taipei City, Taiwan, Arich Enterprise Co., Ltd. specializes in the marketing, promotion, and distribution of pharmaceutical products across Taiwan. Their portfolio includes both prescribed medications and...
Arich Enterprise Co., Ltd. Financial Statement Overview
Summary
Arich shows steady revenue growth (NT$945.7m in 2021 to NT$1.55bn latest) and a stable ~20% gross margin, but profitability is deteriorating: operating margin fell from 9.4% to 6.6% and net income declined to NT$86.8m despite higher sales. The balance sheet is adequate — debt-to-equity of 0.32 and a NT$2.01bn equity base — though borrowings rose sharply from 0.07 and equity funds less than 40% of assets, with ROE of only ~4.3%. The decisive weakness is cash flow: a swing to a NT$1.91bn operating and free cash outflow after a strongly positive 2024, reflecting erratic working-capital swings and weak earnings-to-cash conversion.
Income Statement
63PositiveBalance Sheet
62PositiveCash Flow
30Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.56B | 1.55B | 1.30B | 1.14B | 1.02B | 945.66M |
| Gross Profit | 295.56M | 310.63M | 252.94M | 233.49M | 206.77M | 207.68M |
| EBITDA | 132.40M | 168.86M | 164.16M | 149.03M | 125.63M | 114.45M |
| Net Income | 59.55M | 86.79M | 93.86M | 76.53M | 62.62M | 55.30M |
Balance Sheet | ||||||
| Total Assets | 5.18B | 5.26B | 7.10B | 5.62B | 4.94B | 4.49B |
| Cash, Cash Equivalents and Short-Term Investments | 833.00M | 793.29M | 2.34B | 576.58M | 707.09M | 610.41M |
| Total Debt | 396.05M | 633.95M | 128.65M | 328.98M | 64.48M | 164.76M |
| Total Liabilities | 3.29B | 3.25B | 5.18B | 3.60B | 3.06B | 2.67B |
| Stockholders Equity | 1.89B | 2.01B | 1.92B | 2.02B | 1.88B | 1.82B |
Cash Flow | ||||||
| Free Cash Flow | -58.90M | -1.91B | 2.14B | -303.35M | 116.85M | 322.93M |
| Operating Cash Flow | -36.85M | -1.91B | 2.15B | -274.45M | 139.23M | 336.06M |
| Investing Cash Flow | -46.20M | -43.71M | -68.49M | -68.54M | 48.76M | 30.41M |
| Financing Cash Flow | 112.14M | 408.71M | -407.12M | 206.40M | -77.51M | -197.67M |
Arich Enterprise Co., Ltd. Peers Comparison
Overall Rating
TW:664964Neutral
TW:663762Neutral
TW:416161Neutral- TW:417357Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:6649 | 64Neutral | TWD 1.51B | 45.87 | ― | 2.79% | -24.55% | -85.90% |
| TW:6637 | 62Neutral | TWD 1.46B | 9.93 | ― | 8.26% | -24.93% | -28.65% |
| TW:4161 | 61Neutral | TWD 1.22B | 11.21 | ― | 3.36% | 7.54% | 35.87% |
| TW:4173 | 57Neutral | TWD 1.33B | 22.44 | ― | 5.81% | 10.77% | -35.84% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:4173 | Arich Enterprise Co., Ltd. | 18.00 | -2.74 | -13.22% | |
| TW:4161 | Bioptik Technology, Inc. | 21.10 | -4.55 | -17.73% | |
| TW:6637 | Medical Imaging Corp. | 54.60 | -22.26 | -28.96% | |
| TW:6649 | Taiwan Biomaterial Co., Ltd. | 35.65 | -13.98 | -28.16% | |
| TW:6847 | PuriBlood Medical Co.,Ltd. | 70.40 | -2.46 | -3.38% | |
| TW:6857 | Acer Medical Inc. | 89.90 | -28.60 | -24.14% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026